<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2941">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02541929</url>
  </required_header>
  <id_info>
    <org_study_id>HS-14-00864</org_study_id>
    <nct_id>NCT02541929</nct_id>
  </id_info>
  <brief_title>Fish Oil Brain Delivery Study</brief_title>
  <official_title>Fish Oil Brain Delivery Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Docosahexaenoic acid (DHA) is an essential omega-3 fish oil. DHA is critical to the structure&#xD;
      and function of brain cells.&#xD;
&#xD;
      DHA fish oil has been shown to be beneficial in cognition in several animal studies; however,&#xD;
      this effect in human studies is not clear. It is not known how much dietary fish oil can get&#xD;
      into the human brain. Thus, exploring fish oil delivery in human brains is critical for&#xD;
      designing appropriate interventions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The investigators goal is to study how different people deliver DHA to the brain.&#xD;
&#xD;
        -  The study will only require two visits six months apart and involve taking DHA during&#xD;
           these 6 months.&#xD;
&#xD;
        -  Participants will receive DHA supplements for the study duration and a compensation for&#xD;
           each study visit.&#xD;
&#xD;
        -  Blood and cerebrospinal fluid levels of DHA will be measured before and after taking&#xD;
           DHA.&#xD;
&#xD;
        -  Brain imaging by MRI will be obtained at baseline and at conclusion of study&#xD;
&#xD;
        -  This study will help us learn how much of the ingested DHA goes to the brain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in DHA levels in the CSF following dietary DHA supplementation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain MRI</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>Structural and functional connectivity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Brain Health</condition>
  <arm_group>
    <arm_group_label>DHA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHA (2grams/day) for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (4 capsules per day) for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Docosahexaenoic acid</intervention_name>
    <arm_group_label>DHA</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ages 55 and above&#xD;
&#xD;
          -  at risk of Alzheimer's disease such as family history of dementia&#xD;
&#xD;
          -  women have to be postmenopausal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current smokers (or a recent history of smoking within less than 5 years),&#xD;
&#xD;
          2. Having a history of cardiovascular disease defined by a prior heart attack, coronary&#xD;
             bypass or percutaneous luminal angioplasty, kidney failure or blindness.&#xD;
&#xD;
          3. a diagnosis of cancer in the past 6 months, uncontrolled hyper- or hypothyroidism&#xD;
&#xD;
          4. Taking anti-coagulants such as warfarin&#xD;
&#xD;
          5. Anyone consuming n-3 PUFA capsules for the last 3 months.&#xD;
&#xD;
          6. regular exercisers (&gt;5 X30min of aerobic exercise per week),&#xD;
&#xD;
          7. heavy drinkers (&gt;30 units of alcohol per week). One unit of alcohol is about equal to:&#xD;
             half a pint of ordinary strength beer, lager or cider (3-4% alcohol by volume); or. a&#xD;
             small pub measure (25 ml) of spirits (40% alcohol by volume); or. a standard pub&#xD;
             measure (50 ml) of fortified wine such as sherry or port (20% alcohol by volume)&#xD;
&#xD;
          8. If participants have scores that lie 2 SD outside the means of the neuropsychiatry&#xD;
             tests administered, they will have mild cognitive impairment. Participant's with mild&#xD;
             cognitive impairment are excluded from this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>USC Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.yassinelab.com</url>
    <description>Yassine Lab Website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>March 29, 2020</last_update_submitted>
  <last_update_submitted_qc>March 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Hussein Yassine</investigator_full_name>
    <investigator_title>Dr. Hussein N. Yassine, MD</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Docosahexaenoic acid</keyword>
  <keyword>brain health</keyword>
  <keyword>memory</keyword>
  <keyword>fish oil</keyword>
  <keyword>cognition</keyword>
  <keyword>DHA</keyword>
  <keyword>omega 3 fatty acid</keyword>
  <keyword>brain</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

